Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Liechty B, Xu Z, Zhang Z, Slocum C, Bahadir CD, Sabuncu MR, et al. Machine learning can aid in prediction of IDH mutation from H&E-stained histology slides in infiltrating gliomas. Sci Rep. 2022;12(1):22623.

Greenblatt MB, Shim J-, Bok S, Kim J-. The Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Pathway in Osteoblasts. J Bone Metab. 2022;29(1):1-15.

Dias-Santagata D, Heist RS, Bard AZ, Da Silva AF, Dagogo-Jack I, Nardi V, et al. Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network. Oncologist. 2022;27(11):930-939.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720-1748.

Alhomoud M, Williams A, Magro C, Van Besien K, Vesole DH, Laurence J. Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults. Leuk Lymphoma. 2022;63(2):473-477.

Jang J-, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest. 2022;132(24).

Guo P, Liu Y, Geng F, Daman AW, Liu X, Zhong L, et al. Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability. Nat Cell Biol. 2022;24(1):99-111.

C Miller Q, Al-Hader A, Vance GH, Zhang C. Malignant gastrointestinal neuroectodermal tumour arising in the extrahepatic bile ducts; a rare neoplasm in an unusual anatomic location. BMJ Case Rep. 2022;15(7).

Argani P, Boyraz B, Oliva E, Matoso A, Gross J, Fridman E, et al. GLI1 Gene Alterations in Neoplasms of the Genitourinary and Gynecologic Tract. Am J Surg Pathol. 2022;46(5):677-687.

Wang X, Barrera C, Bera K, Viswanathan VS, Azarianpour-Esfahani S, Koyuncu C, et al. Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors. Sci Adv. 2022;8(22):eabn3966.